In multivariate analyses, CP class independently predicted PFS and OS, while ALBI predicted OS, which highlights the need to assess liver function when selecting systemic therapy and support further studies, including patients with impaired liver function.
Yeokyeong Shin, Young Jae Kim, D. Tai et al.· Annals of Hepatology· 0 citations
INTRODUCTION
After first‑line atezolizumab plus bevacizumab (ATE + BEV) in hepatocellular carcinoma (HCC), optimal second‑line (2L) therapy remains unclear. This study compared the real‑world effectiveness and hepatotoxicity of lenvatinib versus sorafenib as 2L treatment after ATE + BEV.
METHODS
This retrospective, m...
Min-Ji Lee, Su-Bin Lim, J. Shim et al.· Hepatology International· 0 citations
Combined hepatocellular–cholangiocarcinoma (cHCC-CCA) is an uncommon primary liver cancer with distinct histology but overlapping clinical features with hepatocellular carcinoma (HCC). This study compared postoperative outcomes between cHCC-CCA and HCC in patients with very-early or early-stage tumors.
We re...
Yeongseok Hwang, Subin Heo, Y. Yoon et al.· International Journal of Sur...· 0 citations
Background/Aims
Hepatocellular carcinoma (HCC) in younger patients is uncommon, and its clinical behavior and prognosis remain unclear. We aimed to evaluate the characteristics, treatment patterns, and outcomes of young-onset HCC using large-scale datasets.
Methods
This study analyzed two cohorts: the Asan Medical Ce...
Eunju Kim, Min Young Kim, Jina Park et al.· Journal of Liver Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.